Objective To systematically review the clinical efficacy and safety of Yixinshu Capsule（ 益心舒胶囊）（ YXS） combined with western medicine（ WM） in treatment of chronic heart failure（ CHF）. Method Databases such as PubMed

Cochrane library

Embase

Sinomed

CNKI

VIP

and Wanfang data were searched to collect literature from the establishment to 13 October

2017 about treatments of Yixinshu Capsule on CHF. The quality of trials was assessed according to the improved Jadad standard. The meta-analysis and trial sequential analysis（ TSA） using Stata 14 version and TSA v0. 9 were respectively carried out. In addition

the GRADE profile software was used to evaluate the quality of evidences. Results A total of 19 studies including 2291 cases of CHF patients were included eventually. Meta-analysis showed that there were statistical differences（ P < 0. 05） in left ventricular ejection fraction（ LVEF

WMD = 2. 46

95% CI [2. 25

2. 67]

low quality evidence）

left ventricular end diastolic Dimension（ LVEDD

WMD =-2. 04

95% CI [-2. 90

-1. 18]

extreme low quality evidence）

6-minute walking distance（ WMD = 29. 99

95% CI [22. 87

37. 11]

low quality evidence）

and the treatment group was better than control group. Subgroup analysis showed that the clinical efficacy was related to the kinds of CHF. The incidence of adverse reactions was 8. 65% in the treatment group and 6. 73% in the control group. The TSA analysis showed that the evidence of LVEF or 6-minute walking distance was definite

but there was possibly a false positive result of LVEDD. Conclusion YXS combined with WM can increase LVEF and lengthen 6-minute walking distance

reduce the level of LVEDD for CHF with low side effect rate.